
Bristol Myers Squibb Reports Phase 3 Results for Reblozyl in Myelofibrosis Anemia
Bristol Myers Squibb Reports Topline Results from Phase 3 INDEPENDENCE Trial of Reblozyl in Myelofibrosis-Associated Anemia Bristol Myers Squibb (NYSE: BMY), a global leader in hematology and oncology innovation, has announced the topline results from its Phase 3 INDEPENDENCE trial…











